相关实验视频

Updated: Mar 4, 2026

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Published on: June 8, 2022

系统性红斑狼患者血清阿德罗宾水平的降低:一个病例对照研究

Mehrzad Hajialilo¹, Amir Ghorbanihaghjo², Kamran Javidi-Aghdam³

¹Connective Tissue Diseases Research Center Tabriz University of Medical Sciences Tabriz Iran.

Health science reports

|March 3, 2026

概括

在患有全身性红斑狼 (SLE) 的患者中,血清阿德罗宾水平显著降低,这表明与疾病活性和心血管风险的潜在联系. 较低的阿德罗可以预测SLE患者的高血压和抗脂抗体.

科学领域:

内分泌学在内分泌学.
免疫学免疫学免疫学
心血管研究研究心血管研究

背景情况:

系统性红斑狼 (SLE) 是一种复杂的自身免疫性疾病,影响了许多女性,经常与肥胖同时发生.
素是一种类激素,调节新陈代谢,具有抗炎和免疫调节的特性.
了解阿德罗在SLE中的作用对于管理相关的代谢和心血管并发症至关重要.

研究的目的:

在被诊断患有SLE的患者中检查血清阿德罗宾水平.
探索阿德罗宾水平与SLE冠状动脉风险因素之间的关联.
检查阿德罗宾与SLE的临床表现之间的关系.

主要方法:

一项涉及59名SLE患者和30名健康对照者的横截面研究.
使用高灵敏度的人体ELISA套件量化血清阿德罗宾水平.

主要成果:

与对照组相比,SLE患者的血清阿德罗宾水平显著降低 (0.41与0.69 ng/mL相比,p=0.001).
较低的阿德罗宾水平与高脂血症,高血压,炎,血清炎,低补血症和阳性抗脂抗体 (APLA) 有关.
血清阿德罗宾水平与疾病持续时间负相关,并且与高血压和APLAs独立相关.

结论:

在SLE患者中,血清腺水平显著降低.
在SLE中,阿德罗可以作为心血管风险的潜在生物标志物,特别是高血压.
这些发现强调了阿德罗在评估SLE患者心血管风险方面的临床相关性.

关键词:

亚德罗宾 (adropin) 是一种药物.生物标志物生物标志物冠状动脉风险因素是冠状动脉风险因素内皮质功能障碍在内皮质功能障碍系统性红血性狼 (Systemic Lupus Erythematosus) 是一种全身性狼.

更多相关视频

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

Differentiated Mouse Adipocytes in Primary Culture: A Model of Insulin Resistance

Differentiated Mouse Adipocytes in Primary Culture: A Model of Insulin Resistance

Published on: February 17, 2023

相关概念视频

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Nephrotic Syndrome I : Introduction

Nephrotic Syndrome I : Introduction

Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...

Peripheral Artery Disease I: Introduction

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...